Search in:

Diabetes, Metabolic Syndrome and Obesity Volume 9, 2016 - Issue

Submit an article Journal homepage

Open access

Views

CrossRef citations to date

Altmetric

Clinical Trial Report

Comparison of efficacy and safety of two starting insulin regimens in non-Asian, Asian Indian, and East Asian patients with type 2 diabetes: a post hoc analysis of the PARADIGM study

Linong Ji1 Department of Endocrinology, Peking University People’s Hospital, Beijing, People’s Republic of China

Kyung Wan Min2 Department of Endocrinology, Eulji Hospital, Seoul, Republic of Korea

Juliana Oliveira3 Eli Lilly and Company, Indianapolis, IN, USA

Thomas Lew4 Eli Lilly and Company, Taipei, Songshan District, TaiwanCorrespondence[email protected]

Ran Duan3 Eli Lilly and Company, Indianapolis, IN, USA

Pages 243-249 | Published online: 09 Aug 2016

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

Citations (15)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Articles from other publishers (15)

Xiaoyong Yuan, Xiaohui Guo, Junqing Zhang, Xiaolin Dong, Yibing Lu, Wuyan Pang, Shenghong Gu, Elisabeth Niemoeller, Lin Ping, Gaowei Nian & Elisabeth Souhami. (2022) Improved glycaemic control and weight benefit with iGlarLixi versus insulin glargine 100 U/ mL in Chinese people with type 2 diabetes advancing their therapy from basal insulin plus oral antihyperglycaemic drugs: Results from the LixiLan‐L‐CN randomized controlled trial . Diabetes, Obesity and Metabolism 24:11, pages 2182-2191.
Crossref

Qi Pan, Yijun Li, Hailong Wan, Junfen Wang, Binhua Xu, Guoping Wang, Chengxia Jiang, Li Liang, Wei Feng, Jingcheng Liu, Ting Wang, Xia Zhang, Nan Cui, Yiming Mu & Lixin Guo. (2022) Efficacy and safety of a basal insulin + 2‐3 oral antihyperglycaemic drugs regimen versus a twice‐daily premixed insulin + metformin regimen after short‐term intensive insulin therapy in individuals with type 2 diabetes: The multicentre, open‐label, randomized controlled BEYOND‐V trial . Diabetes, Obesity and Metabolism 24:10, pages 1957-1966.
Crossref

Jian Zhou, Si Chen, Jie Cheng, Jiankun Zhu, Ying Lou, Yuqian Bao & Weiping Jia. (2022) Ultra rapid lispro improves postprandial glucose control versus lispro in combination with insulin glargine/degludec in adults with type 2 diabetes: a prospective, randomized, double-blind, phase 3 trial. Science Bulletin 67:17, pages 1785-1791.
Crossref

Jing Liu, Xia Jiang, Binhua Xu, Guoping Wang, Nan Cui, Xia Zhang, Jingcheng Liu, Yiming Mu & Lixin Guo. (2020) Efficacy and Safety of Basal Insulin-Based Treatment Versus Twice-Daily Premixed Insulin After Short-Term Intensive Insulin Therapy in Patients with Type 2 Diabetes Mellitus in China: Study Protocol for a Randomized Controlled Trial (BEYOND V). Advances in Therapy 37:4, pages 1675-1687.
Crossref

Anoop MisraMayur PatelPankaj AgarwalSailesh LodhaNikhil TandonMohan MagdumChittaranjan YajnikRomik GhoshAjit Walekar. (2019) Effectiveness and Safety of Physician-Led Versus Patient-Led Titration of Insulin Glargine in Indian Patients with Type 2 Diabetes Mellitus: A Subanalysis of the Asian Treat to Target Lantus Study (ATLAS). Diabetes Technology & Therapeutics 21:11, pages 656-664.
Crossref

Viswanathan Mohan, Kyu Jeung Ahn, Young Min Cho, Rakesh Kumar Sahay, Chien-Ning Huang, Sanjay Kalra, Manoj Chadha, Indranil Bhattacharya, So Yeon Kim & Erik Spaepen. (2019) Lilly Insulin Glargine Versus Lantus® in Type 2 Diabetes Mellitus Patients: India and East Asia Subpopulation Analyses of the ELEMENT 5 Study. Clinical Drug Investigation 39:8, pages 745-756.
Crossref

Takahisa Hirose, Ching-Chu Chen, Kyu Jeung Ahn & Jacek Kiljański. (2019) Use of Insulin Glargine 100 U/mL for the Treatment of Type 2 Diabetes Mellitus in East Asians: A Review. Diabetes Therapy 10:3, pages 805-833.
Crossref

George Dailey, Harpreet S Bajaj, Terry Dex, Melanie Groleau, William Stager & Aaron Vinik. (2019) Post hoc efficacy and safety analysis of insulin glargine/lixisenatide fixed- ratio combination in North American patients compared with the rest of world. BMJ Open Diabetes Research & Care 7:1, pages e000581.
Crossref

Robyn K. Pollom, Liza L. Ilag, Lyndon B. Lacaya, Tina M. Morwick & Ramón Ortiz Carrasquillo. (2019) Lilly Insulin Glargine Versus Lantus® in Insulin-Naïve and Insulin-Treated Adults with Type 2 Diabetes: A Randomized, Controlled Trial (ELEMENT 5). Diabetes Therapy 10:1, pages 189-203.
Crossref

Xiao-Ling Cai & Li-Nong Ji. (2019) Treatment response between Asian and non-Asian patients with type 2 diabetes. Chinese Medical Journal 132:1, pages 1-3.
Crossref

Xiao Mei Zhang, Peng Fei Li, Jia Ning Hou & Li Nong Ji. (2018) Blood glucose profiles in East Asian and Caucasian injection-naive patients with type 2 diabetes inadequately controlled on oral medication: a pooled analysis. Diabetes/Metabolism Research and Reviews 34:8, pages e3062.
Crossref

Riccardo Candido, Kathleen Wyne & Ester Romoli. (2018) A Review of Basal-Bolus Therapy Using Insulin Glargine and Insulin Lispro in the Management of Diabetes Mellitus. Diabetes Therapy 9:3, pages 927-949.
Crossref

Guang Ning, Tushar Bandgar, Uwe Hehnke, Jisoo Lee & Juliana C. N. Chan. (2017) Efficacy and Safety of Linagliptin in 2681 Asian Patients Stratified by Age, Obesity, and Renal Function: A Pooled Analysis of Randomized Clinical Trials. Advances in Therapy 34:9, pages 2150-2162.
Crossref

Wayne H-H Sheu, Linong Ji, Woo Je Lee, Abdul Jabbar, Jeong Hee Han & Thomas Lew. (2017) Efficacy and safety of premixed insulin analogs in Asian patients with type 2 diabetes: A systematic review. Journal of Diabetes Investigation 8:4, pages 518-534.
Crossref

Linong Ji, Puhong Zhang, Dongshan Zhu, Xian Li, Jiachao Ji, Juming Lu, Xiaohui Guo, Weiping Jia, Jianping Weng, Yangfeng Wu, Wenying Yang, Dajin Zou, Zhiguang Zhou, Changyu Pan, Yan Gao & Satish K. Garg. (2017) Observational Registry of Basal Insulin Treatment (ORBIT) in patients with type 2 diabetes uncontrolled with oral antihyperglycaemic drugs: Real-life use of basal insulin in China. Diabetes, Obesity and Metabolism 19:6, pages 822-830.
Crossref

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Comparison of efficacy and safety of two starting insulin regimens in non-Asian, Asian Indian, and East Asian patients with type 2 diabetes: a post hoc analysis of the PARADIGM study

Articles from other publishers (15)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Comparison of efficacy and safety of two starting insulin regimens in non-Asian, Asian Indian, and East Asian patients with type 2 diabetes: a post hoc analysis of the PARADIGM study

Citations (15)

Articles from other publishers (15)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date